AAPG

Ascentage Pharma Group International (AAPG) SWOT Analysis Analysis (2026)

Invetso Score: 4.2/10 — Balanced · Last Updated: 2026-08-01

Strengths

Negative cash conversion cycle of -43.1 days indicates working-capital efficiency, which is structurally better than peers with longer cash tied up in operations.

Current ratio of 1.22 and quick ratio of 1.18 show near-term liquidity coverage, reducing refinancing pressure relative to more stretched small-cap peers.

Net debt to EBITDA of -0.15 implies net cash or negligible net leverage, which is stronger than leveraged peers and supports balance-sheet flexibility.

The absence of disclosed margin data limits evidence of operating strength, so the company’s structural advantage appears narrower than higher-margin peers.

Weaknesses

Return on invested capital of -48.9% signals severe capital inefficiency, leaving the company materially behind peers that generate positive returns on deployed capital.

Debt-to-equity of 3.76 indicates heavy leverage relative to equity, which is structurally weaker than peers with more conservative capital structures.

Liquidity ratios above 1.0 are adequate but not robust, so the balance sheet remains less resilient than stronger peers during demand or funding shocks.

Missing margin disclosures prevent evidence of durable cost advantage, which weakens the company’s competitive positioning versus better-disclosed peers.

Opportunities

If working-capital discipline persists, the negative cash conversion cycle can continue to free cash versus peers that must fund longer inventory and receivable cycles.

Improving capital efficiency would have outsized impact because the current ROIC gap versus peers leaves substantial room for structural rerating.

Balance-sheet flexibility from low net debt could support operational investment faster than more leveraged peers if execution improves.

Limited segment and growth disclosure leaves open the possibility of underappreciated mix improvement, but the evidence base is too thin to assign a stronger opportunity score.

Threats

Persistently negative ROIC threatens long-term competitiveness because peers with positive returns can compound value while this business destroys capital.

High debt-to-equity increases sensitivity to earnings volatility, making the company more vulnerable than less levered peers if operating conditions weaken.

Without margin disclosure, the market may assume weaker pricing power than peers, which can compress valuation and limit strategic flexibility.

If working-capital benefits reverse, the company could lose the liquidity edge that currently offsets some of its leverage disadvantage versus peers.

Overall Score

AAPG’s structural profile is mixed, with working-capital efficiency and low net debt offset by deeply negative ROIC and elevated leverage versus peers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Ascentage Pharma Group International. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →